Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03585296 | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | PHASE2 | COMPLETED | 22 | — | — | Jul 10, 2018 | Apr 25, 2019 | Feb 17, 2020 | 6 | United States |
Treatment emergent adverse events (TEAEs)graded on a 3 point scale of mild, moderate or severe
| Arm | Type | Description |
|---|---|---|
| ATI-502 | EXPERIMENTAL | ATI-502 topical solution applied daily for four weeks. |
| Name | Type | Description |
|---|---|---|
| ATI-502 | DRUG | Topical Solution |
Inclusion Criteria: 1. Male or non-pregnant, non-nursing female subjects ≥ 18 years old at the time of informed consent. 2. Subject must have diagnosis of AD. 3. Subject must have a diagnosis of moderate or severe AD for a period of ≥6 months prior to the first dose of study medication. 4. Body sur...